サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1362861

ファーマコゲノミクス技術の市場規模、シェア、動向分析レポート：治療分野別、技術別、地域別、セグメント別予測、2023年～2030年

Pharmacogenomics Technology Market Size, Share & Trends Analysis Report By Therapeutic Area, By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ファーマコゲノミクス技術の市場規模、シェア、動向分析レポート：治療分野別、技術別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年09月01日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ファーマコゲノミクス技術市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のファーマコゲノミクス技術市場規模は、2023年から2030年にかけてCAGR 8.7%で拡大し、2030年には123億米ドルに達する見込みです。

診断薬は、新たな生物学的療法のイントロダクション続く薬理ゲノム検査の波に対応しつつあります。これらの検査は費用対効果の高い治療を可能にし、医薬品開発のプロセスにも付加価値を与えます。

さらに、ファーマコゲノミクス検査製品は、患者の治療レジメンの個別化と最適化において医師を支援します。ファーマコゲノミクスとセラノスティクスは統合医療への道を開いています。この特殊な分子診断検査群の急速な進化は、疾患のリアルタイム治療評価の改善に寄与しています。

しかし、ファーマコゲノミクスに基づく検査を医薬品開発のタイムラインに早期に統合し、同時に承認を得るための課題が存在することが、成長の妨げになると予想されます。与えられた治療による個人差や集団差を特定するための臨床試験の適切な設計と実施は、セラノスティクスの成功に必要な特性となっています。

ファーマコゲノミクス技術市場レポートハイライト

  • がん領域は、同領域に相当数の製品が存在することから、最大の売上シェアを占めると推定されます。
  • さらに、精密腫瘍学の研究者たちは、腫瘍の成長を抑えるだけでなく、腫瘍を縮小させるために、様々な種類の組み合わせで複数の薬剤を投与することを想定しています。
  • 前述の事実が、ファーマコゲノミクス技術市場におけるがんの推定収益シェアの原因となっています。
  • ポリメラーゼ連鎖反応（PCR）は、セラノスティクスの技術に関して最大の収益を上げるセグメントでした。
  • PCR技術の使用に伴う利点により、PCRは現在臨床診断の主力技術となっています。
  • さらに、感度を犠牲にすることなくアッセイで得られる再現性のある正確な結果が、推定シェアの原因となっています。
  • 北米地域がファーマコゲノミクス技術市場を独占しているのは、医薬品開発者が自社製品を診断薬と組み合わせることに経済的インセンティブを与えているためです。
  • アジア太平洋市場は、未開拓のビジネスチャンスの獲得に取り組んでいることから、予測期間中に最も速い成長を示すと予測されています。
  • 主要企業は、F Hoffman La Roche、Agilent Technologies、Thermo Fisher Scientific Inc.、GE Healthcare、Pfizer、Qiagen NV、Leica Biosystems Nussloch GmBH、Foundation Medicineなどです。
  • 診断薬企業は、体外診断技術の応用を単なる疾病の検出だけでなく、より広い範囲に広げることで、薬剤開発ツールを提供できるよう、自らを位置づけています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ファーマコゲノミクス技術市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • ファーマコゲノミクス技術市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 ファーマコゲノミクス技術：治療分野の推定・動向分析

  • ファーマコゲノミクス技術市場：重要なポイント
  • ファーマコゲノミクス技術市場：動向と市場シェア分析、2022年および2030年
  • 腫瘍学
    • 腫瘍学の市場推計・予測、2018年から2030年まで
  • 神経学的障害
    • 神経疾患の市場推計・予測、2018年から2030年まで
  • 循環器疾患
    • 心血管疾患の市場推計・予測、2018年から2030年まで
  • 免疫疾患
    • 免疫疾患の市場推計・予測、2018年から2030年まで
  • 感染症
    • 感染症の市場推計・予測、2018年から2030年まで
  • その他
    • その他の市場推計・予測、2018年から2030年まで

第5章 ファーマコゲノミクス技術：技術の推定・動向分析

  • ファーマコゲノミクス技術市場：重要なポイント
  • ファーマコゲノミクス技術市場：動向と市場シェア分析、2022年および2030年
  • PCR
  • In situハイブリダイゼーション
  • 免疫組織化学
  • シーケンス
  • その他

第6章 ファーマコゲノミクス技術市場：地域別の推定・動向分析

  • 地域別の見通し
  • 地域別のファーマコゲノミクス技術市場：主要なマーケットプレースの要点
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • QIAGEN
    • GE HealthCare
    • Agilent Technologies, Inc.
    • F. Hoffmann-La Roche Ltd.
    • FOUNDATION MEDICINE, INC.
    • Thermo Fisher Scientific Inc.
    • Leica Biosystems Nussloch GmBH
    • Pfizer Inc.
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 3 North America pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 4 North America pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 6 U.S. pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 7 Canada pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 8 Canada pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 9 Europe pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 10 Europe pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 11 Europe pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 13 Germany pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 14 UK pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 15 UK pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 16 France pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 17 France pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 18 Italy pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 19 Italy pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 20 Spain pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 21 Spain pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 22 Sweden pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 23 Sweden pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 24 Norway pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 25 Norway pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 26 Denmark pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 27 Denmark pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 31 China pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 32 China pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 33 Japan pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 34 Japan pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 35 India pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 36 India pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 37 Australia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 38 Australia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 39 Thailand pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 40 Thailand pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 41 South Korea pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 42 South Korea pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 43 Australia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 44 Australia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 45 Latin America pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 46 Latin America pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 47 Latin America pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 48 Brazil pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 49 Brazil pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 50 Mexico pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 51 Mexico pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 52 Argentina pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 53 Argentina pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 55 Middle East and Africa pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 56 Middle East and Africa pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 57 South Africa pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 58 South Africa pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 61 UAE pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 62 UAE pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 63 Kuwait pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 64 Kuwait pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Pharmacogenomics technology: Market outlook
  • Fig. 9 Pharmacogenomics technology: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Pharmacogenomics technology market driver impact
  • Fig. 15 Pharmacogenomics technology market restraint impact
  • Fig. 16 Pharmacogenomics technology market strategic initiatives analysis
  • Fig. 17 Pharmacogenomics technology market: Therapeutic area movement analysis
  • Fig. 18 Pharmacogenomics technology market: Therapeutic area outlook and key takeaways
  • Fig. 19 Oncology market estimates and forecasts, 2018 - 2030
  • Fig. 20 Neurological disorders market estimates and forecasts, 2018 - 2030
  • Fig. 21 Cardiovascular diseases market estimates and forecasts, 2018 - 2030
  • Fig. 22 Immunological disorders market estimates and forecasts, 2018 - 2030
  • Fig. 23 Infectious diseases market estimates and forecasts, 2018 - 2030
  • Fig. 24 Others market estimates and forecasts, 2018 - 2030
  • Fig. 25 Pharmacogenomics technology market: Technology movement analysis
  • Fig. 26 Pharmacogenomics technology market: Technology outlook and key takeaways
  • Fig. 27 PCR market estimates and forecasts, 2018 - 2030
  • Fig. 28 In-situ hybridization delivery market estimates and forecasts, 2018 - 2030
  • Fig. 29 Immunohistochemistry market estimates and forecasts, 2018 - 2030
  • Fig. 30 Sequencing market estimates and forecasts, 2018 - 2030
  • Fig. 31 Others market estimates and forecasts, 2018 - 2030
  • Fig. 32 Global Pharmacogenomics technology market: Regional movement analysis
  • Fig. 33 Global Pharmacogenomics technology market: Regional outlook and key takeaways
  • Fig. 34 North America market estimates and forecasts, 2018 - 2030
  • Fig. 35 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 36 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 37 Europe. market estimates and forecasts, 2018 - 2030
  • Fig. 38 UK market estimates and forecasts, 2018 - 2030
  • Fig. 39 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 40 France market estimates and forecasts, 2018 - 2030
  • Fig. 41 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 42 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 43 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 44 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 45 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 46 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 47 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 48 China market estimates and forecasts, 2018 - 2030
  • Fig. 49 India market estimates and forecasts, 2018 - 2030
  • Fig. 50 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 51 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 52 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 53 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 54 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 55 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 56 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 57 Middle East and Africa. market estimates and forecasts, 2018 - 2030
  • Fig. 58 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 59 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 60 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 61 Kuwait market estimates and forecasts, 2018 - 2030
目次
Product Code: GVR-1-68038-940-1

Pharmacogenomics Technology Market Growth & Trends:

The global pharmacogenomics technology market size is expected to reach USD 12.3 billion by 2030, expanding at a CAGR of 8.7% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Diagnostics is coming to grips with the wave of pharmacogenomic tests that are followed by new biological therapy introductions. These tests enable cost-effective treatment and also add value to the process of drug development. Advantages associated with the usage of these tests such as disease risk prediction, patient stratification, and therapeutic response monitoring over the traditional methods is anticipated to a significant source of progress in this pharmacogenomics companion diagnostics market.

In addition, pharmacogenomics testing products aid physicians in individualizing and optimization of the patient's therapeutic regimen. Pharmacogenomics and theranostics are paving the way for integrated medicine. Rapid evolution in this group of specialized molecular diagnostic tests is contributing to improvement for the assessment of real-time treatment of disease.

However, the presence of challenges pertaining to early integration of pharmacogenomic based testing into drug development timelines for gaining the approval simultaneously is anticipated to impede growth. Proper designing and implementation of clinical trials in order to identify individual as well as population variations from a given therapy have become a necessary attribute for the success of theranostics.

Pharmacogenomics Technology Market Report Highlights:

  • Oncology is estimated to account for the largest revenue share owing to the presence of a substantial number of products in this segment
  • Furthermore, precision oncology investigators envision in giving multiple medications, in varied sorts of combinations, in an effort to squelch a tumor rather than just temper its growth
  • Aforementioned fact is responsible for the estimated revenue share of cancer in the pharmacogenomics technology market
  • Polymerase Chain Reaction (PCR) was the largest revenue grossing segment of the with respect to technology for theranostics
  • Advantages associated with the use of the PCR technique makes it the current workhorse of clinical diagnostics
  • Moreover, reproducible and precise results produced with the assays without sacrificing the sensitivity are responsible for the estimated share
  • North American region dominates the pharmacogenomics technology market as a consequence of economic incentives for drug developers to pair their products with diagnostics.
  • Asia Pacific market is projected to showcase the fastest growth over the forecast period as the companies are engaged in capturing untapped opportunities
  • Key players operating include F Hoffman La Roche, Agilent Technologies, Thermo Fisher Scientific Inc., GE Healthcare, Pfizer, Qiagen NV, Leica Biosystems Nussloch GmBH, and Foundation Medicine.
  • Diagnostic companies are positioning themselves to offer theranostic tools by widening the application of in-vitro diagnostic technologies to include more than just disease detection

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Therapeutic area
    • 1.1.2. Technology
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapeutic area outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Pharmacogenomics Technology Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Pharmacogenomics Technology Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Pharmacogenomics Technology: Therapeutic Area Estimates & Trend Analysis

  • 4.1. Pharmacogenomics Technology Market: Key Takeaways
  • 4.2. Pharmacogenomics Technology Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Oncology
    • 4.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.3.1.1. Lung cancer
      • 4.3.1.1.1. Lung cancer market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.1.2. Breast cancer
      • 4.3.1.2.1. Breast cancer market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.1.3. Colorectal cancer
      • 4.3.1.3.1. Colorectal cancer market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.1.4. Cervical cancer
      • 4.3.1.4.1. Cervical cancer market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.1.5. Others
      • 4.3.1.5.1. Others cancer market estimates and forecast 2018 to 2030 (USD Million)
  • 4.4. Neurological Disorders
    • 4.4.1. Neurological disorders market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Cardiovascular Disease
    • 4.5.1. Cardiovascular disease market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Immunological Disorders
    • 4.6.1. Immunological disorders market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Infectious Disease
    • 4.7.1. Infectious disease market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Pharmacogenomics Technology: Technology Estimates & Trend Analysis

  • 5.1. Pharmacogenomics Technology Market: Key Takeaways
  • 5.2. Pharmacogenomics Technology Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. PCR
    • 5.3.1. PCR market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. In-situ Hybridization
    • 5.4.1. In-situ hybridization market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Immunohistochemistry
    • 5.5.1. Immunohistochemistry market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Sequencing
    • 5.6.1. Sequencing market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Pharmacogenomics Technology Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Pharmacogenomics Technology Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. QIAGEN
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. GE HealthCare
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Agilent Technologies, Inc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. F. Hoffmann-La Roche Ltd.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. FOUNDATION MEDICINE, INC.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Thermo Fisher Scientific Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Leica Biosystems Nussloch GmBH
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Pfizer Inc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives